Figure 4.

Genetic deletion of MUC16 reduces PDAC tumorigenicity

(A) Schema of in vitro and in vivo experiments using WT, WT-MUC16^KO, SC, and SC-MUC16^KO cells. (B) Cell migration assay in T3M4 WT, WT-MUC16^KO (2E4), T3M4 SC, and SC-MUC16^KO (1E10) cells. Data were presented as mean ± SD (n = 3; Dunnett’s multiple comparisons test). (C) Matrigel invasion assay inT3M4 WT, WT-MUC16^KO (2E4), T3M4 SC, and SC-MUC16^KO (1E10) cells. Data were presented as mean ± SD (n = 3; Dunnett’s multiple comparisons test). (D and E) Tumor weight (D) and tumor volume (E) of T3M4 WT, WT-MUC16^KO (2E4), T3M4 SC, and SC-MUC16^KO (1E10) cells implanted orthotopic tumors. Data were presented as mean ± SEM (n = 14; Dunnett’s multiple comparisons test). (F) Analysis of tumor metastasis in T3M4 WT, WT-MUC16^KO (2E4), T3M4 SC, and SC-MUC16^KO (1E10) cells implanted tumor-bearing animals (Fisher’s exact test).